Vasomotor symptoms and the homeostatic model assessment of insulin-resistance in Korean postmenopausal women

Dae Hui Kwon¹, Ju Hak Lee¹, Ki-Jin Ryu², Hyun-Tae Park¹, Tak Kim¹

¹Department of Obstetrics and Gynecology, Korea University Medical Center, Korea University College of Medicine, Seoul; ²Ulleung-gun County Hospital, Ulleung, Korea

The aim of this cross-sectional study was to evaluate the association between vasomotor symptoms (VMS) and insulin resistance, which can be postulated by the homeostatic model assessment (HOMA) index. This study involved 1,547 Korean postmenopausal women (age, 45 to 65 years) attending a routine health check-up at a single institution in Korea from January 2010 to December 2012. A menopause rating scale questionnaire was used to assess the severity of VMS. The mean age of participants was 55.22±4.8 years and 885 (57.2%) reported VMS in some degree. The mean HOMA index was 1.79±0.96, and the HOMA index increased with an increase in severity of VMS (none, mild, moderate and severe) in logistic regression analysis (β=0.068, t=2.665, P=0.008). Insulin resistance needs to be considered to understand the linkage between VMS and cardiometabolic disorders.

Keywords: Homeostatic model assessment index; Hot flush; Insulin resistance; Menopause; Vasomotor symptoms

Introduction

Vasomotor symptoms (VMS), such as hot flashes and sweating, are thermoregulatory responses resulting from an inability to maintain the body temperature within a specific range [1]. They are some of the most commonly reported symptoms in postmenopausal women, and disturb women at work, interrupt daily activities, and disrupt sleep [2]. We have recently reported that the presence of VMS is associated with the risk of metabolic syndrome in Korean postmenopausal women [3]. Those findings are in line with the several previous studies reporting the association between VMS and worse metabolic conditions or cardiovascular disease risk factors [4-8]. In contrast, only a few studies have evaluated the relationship between VMS and insulin resistance. Thurston et al. [9] reported the association between hot flashes and insulin resistance by using the homeostatic model assessment (HOMA) index in a US national cohort study. To date, no study has evaluated these associations in the Korean population because of a lack of attention to the significance of such associations.

The aim of this study was to evaluate the association between VMS and insulin resistance, which can be postulated by fasting glucose levels and HOMA index, in Korean postmenopausal women.

Materials and methods

This cross-sectional study included 2,457 Korean postmenopausal women aged 45 to 65 years who were self-referred for a routine health checkup at the Korea University Anam Hospital (Seoul, Korea) between January 2010 and December 2012.

Received: 2015.6.4. Revised: 2015.7.29. Accepted: 2015.8.13. Corresponding author: Tak Kim Department of Obstetrics and Gynecology, Korea University College of Medicine, 73 Inchon-ro, Seongbuk-gu, Seoul 02841, Korea Tel: +82-2-920-6824 Fax: +82-2-921-5357 E-mail: tkim@kumc.or.kr http://orcid.org/0000-0002-1752-237X

Articles published in Obstet Gynecol Sci are open-access, distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2016 Korean Society of Obstetrics and Gynecology

www.ogscience.org
2012. Postmenopausal status was defined as at least 12 consecutive months of amenorrhea with no other medical cause. Each participant provided written informed consent, and this study was approved by the institutional review board of the Korea University Medical Center. The exclusion criteria were as follows: lack of information on menopausal symptoms; lack of data of fasting insulin levels and HOMA index; current hormone use; current medication for diabetes mellitus or dyslipidemia; depressive mood disorders; overt thyroid disorder; surgical menopause; bilateral oophorectomy; past history of chemotherapy or pelvic radiotherapy due to malignant disease; presence of cardiovascular disease such as prior myocardial infarction, angina, stroke, and peripheral arterial diseases; and presence of chronic diseases such as renal failure, liver cirrhosis, and current infectious diseases. Finally, 1,547 postmenopausal women were included in our analysis.

All participants were required to complete an menopause rating scale (MRS) questionnaire, the menopause-specific quality-of-life scale, which was developed to measure the severity of menopause-related complaints by rating a profile of symptoms [10]. To access the severity of VMS, we used a MRS 1 questionnaire. A 5-point rating scale allows the patient to describe the perceived severity of symptoms (none, 0; mild, 1; moderate, 2; severe, 3; and extremely severe, 4) by checking the appropriate box. And for the statistical analyses, extremely severe (4) combined with severe (3), because of small number of women with extremely severe VMS. Thus, we could divide all participants into four subgroups according to the severity of VMS, as following: none (MRS 1 score, 0), mild (1), moderate (2), and severe (3 and 4).

All blood samples were obtained at 9:00 AM after overnight fasting. Fasting blood sugar (FBS), total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglyceride (TG) levels were measured using standard clinical chemistry methods. Insulin level was determined via radioimmunoassay using a commercially available kit from Biosource (Biosource Europe SA, Nivelles, Belgium). HOMA, an index for assessing insulin resistance from fasting glucose and insulin concentrations [11], was calculated using the formula [(fasting insulin×fasting glucose)/405], because the glucose level was measured in mass units (mg/dL). Alcohol intake was categorized according to the frequency of alcohol consumed per week as follows: none or one time versus more than one time per week. Physical exercise was categorized according to the frequency of activity lasting at least 20 minutes per day: none or one time versus more than one time per week. Current smoking was defined as current cigarette smoking at the time of the visit.

Continuous variables are presented as mean with standard deviations, and categorical variables are expressed as counts and percentages. Metabolic characteristics of the subgroups divided by the severity of VMS were compared using the ANOVA test with Bonferroni post-hoc test for continuous variables and Pearson’s χ² test for categorical variables. Statistical analysis for linear trends between the severity of VMS and HOMA index was conducted using linear regression analysis method. All statistical analyses were performed using IBM SPSS ver. 21.0 (IBM Corp., Armonk, NY, USA). All P-values were based on 2-sided tests, with statistical significance defined as P<0.05.

**Results**

A total of 1,547 postmenopausal women (mean age, 55.2±4.8 years) were included in this study. We reviewed data including the possible factors of metabolic syndrome and VMS: age, age at menopause, body mass index, systolic blood pressure, diastolic blood pressure, waist circumference, C-reactive protein, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, TG, insulin, FBS levels, HOMA index, alcohol intake, current smoking and physical exercise level. The participants were not obese (body mass index, 23.4±3.0) or hypertensive (systolic blood pressure, 108.5±16.2; diastolic blood pressure, 66.2±10.9) and were not diabetic (insulin, 7.7±3.6; FBS, 93.3±12.6). We divided the patients into several groups according to the severity of their VMS (none, mild, moderate, and severe), and metabolic characteristics of those subgroups are presented in Table 1. Women with any degree of VMS were younger and had shorter duration after menopause than women without VMS. Women with severe VMS were more obese than women without VMS, and had higher HOMA index and fasting insulin levels than women without VMS or women with mild VMS (Table 1).

Fig. 1 show that the HOMA index tended to increase in participants reporting higher scores on MRS 1. Logistic regression analyses were performed to assess the linear association between VMS and insulin resistance. The HOMA index seemed to increase with an increase in the MRS 1 scores which repre-

**www.ogscience.org**
Dae Hui Kwon, et al. Vasomotor symptoms and insulin resistance

After adjusting for confounding factors including age, years-since-menopause, BMI, waist circumference, systolic BP, diastolic BP, total cholesterol, triglyceride, C-reactive protein, insulin, FBS, and exercise, there was no remained statistical significance of relationship between HOMA index and severity of VMS on multivariate regression analyses ($\beta=0.032$, $t=1.376$, $P=0.169$).

## Discussion

We evaluated the association between menopausal symptoms and insulin resistance in postmenopausal women. In this study, the HOMA index significantly increased in postmenopausal women with high scores on MRS 1. To the best of our knowledge, this study is the first to report an association between insulin resistance and VMS in Korean postmenopausal women. Few previous studies have focused on this association. In a study of 3075 US women in menopausal transition, hot flashes were associated with an increased HOMA index.

---

**Table 1.** Metabolic characteristics of the subgroups divided by the severity of vasomotor symptoms (N=1,547).

| Severity of vasomotor symptoms (MRS 1 score) | None (0) (n=652) | Mild (1) (n=508) | Moderate (2) (n=240) | Severe (3 & 4) (n=137) | P-value$^a$ | Post-hoc$^b$ |
|--------------------------------------------|------------------|-----------------|----------------------|-----------------------|------------|-------------|
| Age (yr)                                   | 55.9±5.1         | 54.7±4.6        | 54.9±4.5             | 54.6±4.1              | <0.001     | 1–2, 1–3, 1–4 |
| Years-since-menopause (yr)                 | 6.66±4.75        | 5.20±4.28       | 5.62±4.81            | 4.88±4.05             | <0.001     | 1–2, 1–3, 1–4 |
| BMI (kg/m$^2$)                             | 23.2±2.9         | 23.3±3.1        | 23.7±3.1             | 24.0±2.8              | 0.012      | 1–4         |
| Waist circumference (cm)                   | 82.8±7.8         | 83.0±8.1        | 84.1±8.2             | 84.6±7.6              | 0.020      |             |
| Systolic BP (mmHg)                         | 107.8±16.3       | 108.6±16.1      | 109.6±17.0           | 109.3±14.4            | 0.444      |             |
| Diastolic BP (mmHg)                        | 65.9±11.1        | 66.2±10.7       | 66.9±10.7            | 65.9±10.5             | 0.700      |             |
| Total cholesterol (mg/dL)                  | 199.1±33.7       | 202.4±34.8      | 201.1±33.5           | 204.5±32.0            | 0.224      |             |
| HDL (mg/dL)                                | 57.8±14.2        | 56.0±13.8       | 55.7±14.1            | 55.8±12.5             | 0.061      |             |
| LDL (mg/dL)                                | 99.3±20.0        | 101.3±20.3      | 101.1±19.8           | 102.8±21.0            | 0.154      |             |
| Triglyceride (mg/dL)                       | 105.0±35.9       | 117.9±78.5      | 110.7±65.2           | 117.0±59.0            | 0.006      | 1–2         |
| C-reactive protein (mg/L)                  | 1.15±3.39        | 1.38±4.83       | 1.31±3.62            | 1.34±3.35             | 0.791      |             |
| Insulin (µIU/mL)                           | 7.53±3.40        | 7.46±3.53       | 7.83±3.51            | 8.71±4.84             | 0.002      | 1–4, 2–4    |
| FBS (mg/dL)                                | 92.9±13.1        | 93.5±13.5       | 94.0±10.8            | 92.8±8.8              | 0.635      |             |
| HOMA index                                 | 1.75±0.89        | 1.76±0.97       | 1.84±0.92            | 2.03±1.23             | 0.011      | 1–4, 2–4    |
| Alcohol (≥2 times/wk)                      | 223 (33.7)       | 184 (36.2)      | 89 (37.1)            | 57 (41.6)             | 0.320      |             |
| Current smoking                            | 16 (2.4)         | 10 (2.0)        | 6 (2.5)              | 5 (3.6)               | 0.722      |             |
| Exercise (≥2 times/wk)                     | 397 (60.0)       | 318 (62.6)      | 128 (53.3)           | 83 (60.6)             | 0.118      |             |

Data are expressed as mean±standard deviation or number (%).

MRS 1, menopause rating scale questionnaire 1; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; FBS, fasting blood sugar; HOMA, homeostatic model assessment.

$^a$Statistical comparisons were conducted using ANOVA for continuous variables and Pearson’s $\chi^2$ test for categorical variables; $^b$Bonferroni post-hoc tests are used. 1–2, significant differences between none and mild; 1–3, significant differences between none and moderate; 1–4, significant differences between none and severe; 2–3, significant differences between mild and moderate; 2–4, significant differences between mild and severe; 3–4, significant differences between moderate and severe (statistical significance defined as $P<0.05$).
And some studies are now focusing on the relationship between VMS and cardiovascular diseases or metabolic syndrome. Our previous study based on data obtained from the same population with present study revealed that the presence of VMS is associated with the risk of metabolic syndrome in postmenopausal women [3].

Insulin resistance is a pathological condition characterized by decreased sensitivity of peripheral tissues to insulin which is the pathological basis for diabetes and several cardiovascular diseases [12]. Estrogen is shown to influence insulin receptor expression on those tissues, especially on adipocytes, thus its’ level is significantly associated to insulin resistance and metabolic syndrome [13,14]. Given that the appearance of VMS may affect estrogen deprivation [15], changes in circulating estrogen levels during peri- or postmenopausal period might work as link between the VMS and insulin resistance. However, data of circulating estrogen levels were not available in present study. On the other hands, insulin resistance is pervasive features of obesity, increasing with weight gain and diminishing with weight loss [16]. An increase in the total and abdominal adiposity also can raise core body temperature and it may increase the occurrence and severity of VMS [17]. Thus obesity might be an important shared risk factor of VMS and insulin resistance. Third, the possibility of the role of the physiological system cannot be ruled out. The sympathetic predominance of VMS might alter the glucose availability and pancreatic insulin production [9]. The hypothalamic-pituitary-adrenal axis may play a role between both conditions [18]. All of these multiple mechanisms, which require further studies, may explain the association between VMS and insulin resistance.

VMS are the main indication for menopausal hormone therapy (MHT) in postmenopausal women. An important implication can be drawn from this statement. If VMS are significantly associated with insulin resistance, as shown in our study, we can postulate that women with insulin resistance would have a greater need for MHT than those without insulin resistance. From this context, the possibility of the curative effect of MHT in patients with insulin resistance should be considered. One meta-analysis reported the effects of MHT in women with type 2 diabetes [19]. In this study, pooled results of 107 trials showed that MHT reduced abdominal fat, HOMA index, and new-onset diabetes in women without diabetes. The importance of the relationship between VMS and insulin resistance and the possibility of MHT use for the treatment of postmenopausal women with diabetes are understood in this context. On the contrary, it is theoretically possible that MHT in women with severe VMS may make the cardiovascular risks worse because women with insulin resistance are likely to have more atherosclerosis [20].

In conclusion, our results suggest that VMS in postmenopausal women are associated with increased insulin resistance. VMS and insulin resistance are associated with each other in many metabolic aspects. Thus, clinicians should pay more attention to postmenopausal women complaining of VMS, because they can be considered to be at high risk of many types of metabolic diseases.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

References

1. Herber-Gast GC, Mishra GD, van der Schouw YT, Brown WJ, Dobson AJ. Risk factors for night sweats and hot flushes in midlife: results from a prospective cohort study. Menopause 2013;20:953-9.
2. Hunter M. The south-east England longitudinal study of the climacteric and postmenopause. Maturitas 1992;14:117-26.
3. Ryu KJ, Park HT, Kwon DH, Yang KS, Kim YJ, Yi KW, et al. Vasomotor symptoms and metabolic syndrome in Korean postmenopausal women. Menopause 2015;22:1239-45.
4. Thurston RC, Sowers MR, Sutton-Tyrrell K, Everson-Rose SA, Lewis TT, Edmundowicz D, et al. Abdominal adiposity and hot flashes among midlife women. Menopause 2008;15:429-34.
5. Gast GC, Grobbee DE, Pop VJ, Keyzer JJ, Wijnands-van Gent CJ, Samsioe GN, et al. Menopausal complaints and metabolic syndrome in Korean postmenopausal women. Menopause 2015;22:1239-45.
6. Gast GC, Samsioe GN, Grobbee DE, Nilsson PM, van der Schouw YT. Vasomotor symptoms, estradiol levels

Embargo expires on May 1, 2016. www.ogscience.org

Obstetrics & Gynecology Science
Vol. 59, No. 1, 2016

Vol. 59, No. 1, 2016
and cardiovascular risk profile in women. Maturitas 2010;66:285-90.
7. Chedraui P, Hidalgo L, Chavez D, Morocho N, Alvarado M, Huc A. Menopausal symptoms and associated risk factors among postmenopausal women screened for the metabolic syndrome. Arch Gynecol Obstet 2007;275:161-8.
8. Lee SW, Jo HH, Kim MR, Kwon DJ, You YO, Kim JH. Association between menopausal symptoms and metabolic syndrome in postmenopausal women. Arch Gynecol Obstet 2012;285:541-8.
9. Thurston RC, El Khoudary SR, Sutton-Tyrrell K, Crandall CJ, Sternfeld B, Joffe H, et al. Vasomotor symptoms and insulin resistance in the study of women’s health across the nation. J Clin Endocrinol Metab 2012;97:3487-94.
10. Hauser GA, Huber IC, Keller PJ, Lauritzen C, Schneider HP. Evaluation of climacteric symptoms (Menopause Rating Scale). Zentralbl Gynakol 1994;116:16-23.
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
12. Hou ZM, Sun Q, Liu YZ, Chen TF, Tang N. Effects of insulin resistance on myometrial growth. Int J Clin Exp Med 2015;8:1552-7.
13. Clapauch R, Mourao AF, Mecenas AS, Maranhao PA, Rossini A, Bouskela E. Endothelial function and insulin resistance in early postmenopausal women with cardiovascular risk factors: importance of ESR1 and NOS3 polymorphisms. PLoS One 2014;9:e103444.
14. Lo JC, Zhao X, Scuteri A, Brockwell S, Sowers MR. The association of genetic polymorphisms in sex hormone biosynthesis and action with insulin sensitivity and diabetes mellitus in women at midlife. Am J Med 2006;119(9 Suppl 1):S69-78.
15. Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res 2002;57:257-75.
16. Eckel RH. The metabolic syndrome. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison’s principles of internal medicine. 18th ed. New York (NY): McGraw-Hill Companies; 2012. p.1992-7.
17. Freedman RR. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 2005;23:117-25.
18. Cagnacci A, Canoletta M, Caretto S, Zanin R, Xholli A, Volpe A. Increased cortisol level: a possible link between climacteric symptoms and cardiovascular risk factors. Menopause 2011;18:273-8.
19. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538-54.
20. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest 2006;116:1813-22.